1. Home
  2. COGT vs LIND Comparison

COGT vs LIND Comparison

Compare COGT & LIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • LIND
  • Stock Information
  • Founded
  • COGT 2014
  • LIND 1979
  • Country
  • COGT United States
  • LIND United States
  • Employees
  • COGT N/A
  • LIND N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • LIND Transportation Services
  • Sector
  • COGT Health Care
  • LIND Consumer Discretionary
  • Exchange
  • COGT Nasdaq
  • LIND Nasdaq
  • Market Cap
  • COGT 545.3M
  • LIND 502.2M
  • IPO Year
  • COGT 2018
  • LIND N/A
  • Fundamental
  • Price
  • COGT $4.81
  • LIND $10.44
  • Analyst Decision
  • COGT Buy
  • LIND Strong Buy
  • Analyst Count
  • COGT 7
  • LIND 3
  • Target Price
  • COGT $14.00
  • LIND $15.67
  • AVG Volume (30 Days)
  • COGT 1.3M
  • LIND 302.7K
  • Earning Date
  • COGT 05-06-2025
  • LIND 05-06-2025
  • Dividend Yield
  • COGT N/A
  • LIND N/A
  • EPS Growth
  • COGT N/A
  • LIND N/A
  • EPS
  • COGT N/A
  • LIND N/A
  • Revenue
  • COGT N/A
  • LIND $670,834,000.00
  • Revenue This Year
  • COGT N/A
  • LIND $12.38
  • Revenue Next Year
  • COGT N/A
  • LIND $10.15
  • P/E Ratio
  • COGT N/A
  • LIND N/A
  • Revenue Growth
  • COGT N/A
  • LIND 15.71
  • 52 Week Low
  • COGT $3.72
  • LIND $6.76
  • 52 Week High
  • COGT $12.61
  • LIND $14.34
  • Technical
  • Relative Strength Index (RSI)
  • COGT 44.64
  • LIND 66.87
  • Support Level
  • COGT $4.55
  • LIND $9.34
  • Resistance Level
  • COGT $5.89
  • LIND $10.68
  • Average True Range (ATR)
  • COGT 0.38
  • LIND 0.49
  • MACD
  • COGT 0.09
  • LIND 0.26
  • Stochastic Oscillator
  • COGT 34.55
  • LIND 82.31

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About LIND Lindblad Expeditions Holdings Inc.

Lindblad Expeditions Holdings Inc provides expedition cruising and adventure travel services. The company operates in two segments: Lindblad and Land Experiences, of which Lindblad generates the vast majority of its revenue. It offers itineraries that feature up-close encounters with wildlife, nature, history, and culture, as well as promote guest empowerment and interactivity. It operates expeditions on intimately-scaled ships and interaction between guests, crew, and the teams of scientists, naturalists, researchers, and photographers that participate in the expeditions. Lindblad operates a fleet of twelve owned expedition ships and five seasonal charter vessels under the Lindblad brand.

Share on Social Networks: